TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07288580: A Phase Ⅰ/Ⅱ, Multicenter, Single-arm, Open-label Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHT102 Injection in Pediatric Patients With Biallelic hOTOF Mutations

Sponsor: Shanghai Euhearing Therapeutics Co., Ltd · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 30 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,002,180

Rescue Site Savings

+$5,954,420

Unlock Full NCT07288580 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07288580 Rescue Dossier →